STOCK TITAN
  1. Home
  2. News
  3. TAK

Takeda Pharmaceutical Co - TAK STOCK NEWS

Welcome to our dedicated news page for Takeda Pharmaceutical Co (Ticker: TAK), a resource for investors and traders seeking the latest updates and insights on Takeda Pharmaceutical Co.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Takeda Pharmaceutical Co's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Takeda Pharmaceutical Co's position in the market.

News
Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer
Rhea-AI Summary
<p>Takeda (NYSE:TAK) has received a positive recommendation from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) for the approval of fruquintinib, a targeted therapy for previously treated metastatic colorectal cancer (mCRC). If approved by the European Commission, fruquintinib will be a novel treatment in the EU, highlighting its status as the first therapy to inhibit all three vascular endothelial growth factor receptors (VEGFR-1, -2, -3) for mCRC in over a decade. The therapy showed significant improvements in overall survival and progression-free survival in Phase 3 FRESCO-2 trials compared to the current standard care.</p><p>Fruquintinib's potential impacts are substantial, offering a new chemotherapy-free option that improves patient outcomes. It has already been approved in the U.S. under the brand name FRUZAQLA® as of November 2023, and launched in China in 2018 as ELUNATE®. Key safety information includes risks such as hypertension, hemorrhagic events, infections, and hepatotoxicity among others.</p>
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.31%
Tags
none
-
News
Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder
Rhea-AI Summary
Neurocrine Biosciences announces positive Phase 2 data for NBI-1065845 in adults with Major Depressive Disorder. The SAVITRI™ study met primary and key secondary endpoints, showing statistically significant reductions in MADRS total score at both Day 28 and Day 56. NBI-1065845 was well-tolerated with low discontinuation rates. The data suggests potential as a first-in-class treatment for MDD.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.81%
Tags
clinical trial
-
News
Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs
Rhea-AI Summary
Takeda, Astellas, and Sumitomo Mitsui Banking have announced a master agreement to establish a joint venture company dedicated to the incubation of early drug discovery programs in Japan. The new company aims to advance innovative drug discovery programs, foster entrepreneurship, and create start-up companies to unleash the potential of the drug discovery ecosystem in Japan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.32%
Tags
none
News
U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
Rhea-AI Summary
Takeda's ENTYVIO (vedolizumab) receives FDA approval for subcutaneous administration in maintenance therapy for moderately to severely active Crohn’s disease. The drug is now available in the U.S. for both IV and SC administrations for the treatment of adults with Crohn’s disease and ulcerative colitis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.61%
Tags
fda approval
-
News
Takeda Announces New U.S. Corporate Social Responsibility Program Partners to Build Equity through STEM Education and Access to Nutritional Food
Rhea-AI Summary
Takeda announces $14.6 million investment in CSR program, welcoming eight new grant partners. Total contributions reach $54.1 million since 2021. Focus on Food is Health and Building STEM Foundations to promote equity in under-resourced communities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.11%
Tags
none
-
News
Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAE
Rhea-AI Summary
Takeda's 'In Their Shoes' initiative sheds light on the daily struggles of IBD patients in the UAE, aiming to raise awareness and empathy through a 24-hour simulation. IBD, a chronic inflammatory condition affecting the gastrointestinal tract, has seen a rise in incidence globally, including in newly industrialized countries like the UAE.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.39%
Tags
none
News
Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting
Rhea-AI Summary
Takeda (TAK) announces Board of Directors changes, proposing new candidates and appointing a new CFO. Mr. Milano Furuta to succeed Mr. Constantine Saroukos as CFO. Several directors to join the Board with defined roles and tenures.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.39%
Tags
management
-
News
Takeda Announces Approval of ADZYNMA® Intravenous Injection 1500 (apadamtase alfa /cinaxadamtase alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
Rhea-AI Summary
Takeda gains approval for ADZYNMA, a groundbreaking treatment for congenital thrombotic thrombocytopenic purpura (cTTP) in Japan. ADZYNMA is the first recombinant ADAMTS13 enzyme replacement therapy for cTTP, addressing acute events and chronic symptoms. The approval is based on positive interim analysis results from a Phase 3 trial, showcasing efficacy, safety, and tolerability. ADZYNMA demonstrated a significant reduction in acute TTP events compared to plasma-based therapies, with a lower incidence of treatment-related adverse events.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.7%
Tags
none
-
News
Takeda Announces U.S. FDA Approval of Supplemental New Drug Application (sNDA) for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL
Rhea-AI Summary
Takeda's ICLUSIG receives FDA approval as the first targeted treatment for frontline Ph+ Acute Lymphoblastic Leukemia in the U.S., showing superior results in MRD-negative Complete Remission rates compared to imatinib.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.03%
Tags
fda approval
News
Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia
Rhea-AI Summary
Takeda announces positive Phase 2 results for mezagitamab in patients with primary immune thrombocytopenia, showing safety, tolerability, and efficacy. Plans for a global Phase 3 trial in fiscal year 2024. Mezagitamab demonstrates promising platelet response rates and potential disease remission in ITP patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.35%
Tags
clinical trial
Stock TAK logo
Takeda Pharmaceutical Co

NYSE:TAK

TAK Rankings

#302 Ranked by Market Cap
#1877 Ranked by Stock Gains
#655 Ranked by Dividends

TAK Stock Data

42.46B
1.55B
0%
2.67%
0.26%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Japan
Chuo Ku

About TAK

The Takeda Pharmaceutical Company Limited is a Japanese multinational pharmaceutical company, with partial American and British roots. It is the largest pharmaceutical company in Asia and one of the top 20 largest pharmaceutical companies in the world by revenue.